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ABSTRACT
Homocysteine is a natural occurring aminothiol. It is an intermediate product in the
metabolism of methionine. Methionine is an essential amino acid required for protein
synthesis. Metabolic irregularities disrupt homocysteine levels in plasma. Elevated
homocysteine levels are directly linked to folate and cobalamin (vitamin B12)
deficiencies, and are an independent risk factor for cardiovascular diseases. High
homocysteine levels have also been associated with Alzheimer’s, osteoporosis, renal
failure, cancer, birth defects and pregnancy complications. The association of elevated
homocysteine levels with cardiovascular disease and other diseases has generated great
interest in the detection of homocysteine.
An optical method for the detection of homocysteine has been developed using
fluorescein mono- and dialdehydes. Selectivity for homocysteine was achieved based on
the characteristic differences between 5- and 6-membered ring heterocyclic amines
formed upon the reaction with fluorescein mono- and dialdehydes. 6-membered ring
homocysteine-derived thiazinane-4-carboxylic acids were found to be more basic than 5membered cysteine-derived thiazolidine-4-carboxylic acids. Fluorescence enhancement
in response to homocysteine was thus attained by tuning pH and excitation wavelengths.
Furthermore, the design and synthesis of a more sensitive fluorophore, fluorescein tri
aldehyde has been accomplished based on the aforementioned findings to enable the
detection of homocysteine at physiological levels. Calculations of Mulliken charges
revealed that the formation of thiazinanes results in modulation of the electron density on
the fluorophore leading to higher fluorescence.
i
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CHAPTER 1 INTRODUCTION
The low molecular weight thiols homocysteine (Hcy), cysteine (Cys) and glutathione
(GSH) play a crucial role in metabolism and homeostasis. They are vital cell components
that serve as antioxidants to maintain the redox balance in the human body. Aberrant
levels in their concentrations results in metabolic disturbances that are linked to several
diseases [1].
1.1 Hcy, Cys and GSH: structural features and functions.
Hcy is a sulfur containing non-essential amino acid. It is a metabolic intermediate
derived from the essential sulfur containing amino acid methionine (Met). Hcy shares
structure resemblance with another low molecular weight thiol, Cys, with the exception
that it contains one more methylene group in its side chain, as shown in Figure 1-1.
Thiol-like properties of Hcy are common to GSH and Cys.

Figure 1-1. Structures of selected biological thiols

Hcy is present in various forms in human plasma. Total Hcy is the sum of all
different species of Hcy i.e. protein bound, oxidized and reduced or free forms and it is
1

referred as tHcy [2]. The major form is disuflude bound to proteins, mainly albumin.
The protein bound form of Hcy constitutes 70-80 % of total Hcy. Other oxidized forms
such as Hcy-Hcy (Hcy disulfide) accounts for 5-10%, Hcy-Cys disulfide accounts for 510% of the tHcy, and reduced Hcy sulfhydril accounts for less than 1% in human plasma.
In general, the levels of tHcy in a healthy humans is approximately 5-15 μM, and
increases with ageing. The condition in which the level of Hcy in human plasma rises
above 15 μM is called ‘hyperhomocysteinemia’. There are three stages of
hyperhomocysteinemia; mild, in which the Hcy level is 15-30μM; moderate, in which
the level is 30-100μM and for the level above >100 μM of Hcy, it is termed as severe
hyperhomocysteinemia [3].
Cys is the lowest molecular weight biological thiol. Among the three major
biological thiols, cysteine is the most abundant extracellular thiol. It varies from 150-300
μM [4, 5]. Cys is produced during Hcy metabolism. Therefore, Hcy and Cys levels are
highly related to each other. Cys plays an essential role in protein synthesis, redox
chemistry and peptide cross-linking, detoxification and other metabolic processes [6, 7].
GSH is a tripeptide wherein glycine and Cys are linked by normal peptide linkage
and amine group of Cys is attached to the carbonyl group of glutamate side chain via
gamma peptide linkage. Thus, GSH is indirectly linked to homocysteine metabolism. It is
known for its antioxidant properties. It is also involved in gene expression, cell
proliferation and apoptosis [8]. GSH concentrations are very high in cells. They range
from 1 to 5 mM, whereas its concentration in plasma is 1 to 6 μM [5, 8].

2

1.2 Metabolism of Hcy
The metabolism of Hcy is intricately linked to the metabolic pathway of methionine, one
of the essential amino acids [9]. Hcy is thus a vital part of cellular homeostasis in human
body. Methionine is essential for protein synthesis; it acts as a methyl donor for the
synthesis of a wide range of vital methylated compounds such as DNA, RNA etc. [10].
Hcy is the key intermediate of the transsulfuration pathway to produce several other
sulfur-bearing amino acids such as, cystathionine, Cys, taurine, GSH, etc. [11]. Hcy is the
foremost source of sulfur for inorganic sulfate. It also is linked to polyamine
biosynthesis. Furthermore, Hcy plays a crucial part in folate metabolism, as well as in the
catabolism of choline and betaine [10].
Hcy metabolism is shown in Figure 1-2. Hcy levels depend on the proper
functioning of the enzymes involved in its metabolism. These include enzymes involved
in the remethylation reaction pathway to form methionine (Met), such as betaine
methyltransferase (BMT), S-adenosylhomocysteine hydrolase (SAHH), methionine
synthase (MS), methionine adenosyltransferase (MAT) and S-adenosylmethione (SAdoMet)-dependent methyl transferases e.g., glycine methyltransferase. Methionine
synthase

depends

on

methionine

synthase

reductase,

vitamin

B12

and

5-

methyltetrahydrofolate obtained from methylenetetrahydrofolate reductase (MTHFR). A
second pathway in Hcy metabolism is transsulphuration to produce cystathione, Cys and
inorganic sulphates. This latter pathway mainly involves the enzyme cystathionine βsynthase (CBS) [12].
3

In the remethylation step, Hcy is converted to Met by a complex 5methyltetrahydrofolate- dependent reaction [13]. 5-methyl tertrahydrofolate is produced
by 5,10-methylenetetrahydrofolate in the presence of MTHFR. The remethylation
reaction is catalyzed by MS. This enzyme gets reductively methylated by methionine
synthase reductase. The synthesis of methionine synthase reductase requires cobalamine
(vitamin B12) and S-AdoMet. Additionally, Hcy can be remethylated to Met in a process
promoted by betaine via betaine methyl transferase (BMT). Remethylating enzyme BMT
is only found in liver, kidney and brain. MS, however, it has a wide tissue distribution
[14].
Met is transformed to its active form S-AdoMet. This reaction is catalyzed by
methionine adenosyl transferase (MAT) [13]. S-AdoMet acts as a methyl donor for the
production of a large number methylated biomolecules such as methylated DNA, RNA,
lipids and proteins [14]. To date, 39 S-AdoMet dependent methyl transferases have been
discovered in mammals [1]. After donating a methyl group, S-AdoMet becomes Sadenosylhomocysteine (S-AdoHcy). To complete the Hcy metabolism cycle, S-AdoHcy
undergoes hydrolysis to produce Hcy and adenosine. The enzyme Ado-Hcy hydrolase
catalyzes this hydrolysis [14]. S-AdoMet also undergoes decarboxylation to provide a
propyl amine moiety for the synthesis of spermine and spermidine[13]. However, this
reaction consumes less than 10% of the total S-AdoMet[15]. (Figure 1-3)

4

Figure 1-2. Homocysteine-methionine metabolism.
Enzymes involved in in Hcy metabolism : MAT-methionine adenosyltransferase, X-MT-various S-AdoMet
dependent
methyltransferases,
SAHH-S-adenosylhomocysteine
hydrolase,
MS-methionine
synthase, BMT-betaine methyltransferase, MTHFR methylenetetrahydrofolate reductase, CBS cystathioni
ne β-synthase, γCL, γ-cystathionase, SHM serine hydroxymethylase. This figure was adopted from [14]
and redrawn with some modifications.

In the alternate Hcy transsulfuration [11] pathway, the first step involves
condensation of Hcy with serine to produce cystathionine. This condensation takes place
in the presence of cystathionine β-synthase (CBS). Pyridoxal 5phosphate (vitamin B6) is
a cofactor for CBS. In the second step, cystathionine converts to Cys and a by-product αoxo butyrate. The enzyme - cystathionase catalyzes this step and, like CBS, requires
pyridoxal 5phosphate [14]. Cys is essential for the synthesis of the antioxidant
glutathione. By a variety of enzymatic reactions and oxidation, cysteine produces
5

inorganic sulfates [16].
1.2.1 Summary of enzymes involved in the regulation of Met and Hcy
(1). ATP: L-Methionine S-Adenosyltransferase: This enzyme facilitates the formation of
vitally important S-AdoMet by catalyzing the transfer of adenosyl moiety from ATP to
Met [14]. This reaction takes place in the presence of Mg2 and K [17]. Two of the forms
of S-AdoMet are specific to liver i.e. a tetramer MAT(I), which is an α form and a dimer
MAT(III), which is a β form. The gene MAT1A encodes both forms in the liver. This
gene is capable of reacting with high Met immediately.
(2). S-AdoMet-dependent methyltransferases (glycine N-methyltransferase GNMT):
GNMT is one of the S-AdoMet-dependent methyltransferases that converts glycine to
sarcosine by the transfer of a methyl group from S-AdoMet [14]. By donating a methyl
group, S-AdoMet transforms to S-AdoHcy. S-AdoHcy is an inhibitor of the enzyme MS.
Any disturbance in the ratio of S-AdoMet to S-AdoHcy affects the activity of MS [14].
(3). S-AdoHcy Hydrolase: This enzyme has a binding site for adenosine. Therefore, it
facilitates S-AdoHcy hydrolysis to form Hcy and release adenosine [9].
(4). Methionine Synthase (5-Methyltetrahydrofolate: Homocysteine Methyltransferase ):
This enzyme catalyzes the remethylation reaction to form Met [9]. MS assists the transfer
of the methyl group from 5-methyl THF to Hcy to form Met. MS maintains the folate and
Met cycle to endow enough Met for S-AdoMet-dependent transmethylation reactions
[14]. This enzyme encompasses zinc and four domains to bind Hcy, S-AdoMet,
cobalmine cofactor and methylene tetrahydrofolate [18].
6

(5). Methionine Synthase Reductase (Methionine Synthase Cob(II)alamine Reductase):
MS would be inactive if the cobalamine factor exists as cob(II)alamine [14]. To activate
methionine synthase, cob(II)amine needs to be reduced to cob(I)alamine. Reduction
requires conversion of S-AdoMet to S-AdoHcy. This overall process is expedited by the
enzyme methionine synthase reductase [14]. A complete reaction mechanism is described
in Figure1-4.

Figure 1-3. Redox and methylation reaction mechanism of methionine synthase:
methionine synthase (MS) reductase; and tetrahydrofolate (THF). This figure was adopted form [14] and
redrawn with some modifications.

(6). Betaine Homocysteine Methyltransferase (BMT): This enzyme also transforms Hcy
to Met [14]. Betaine acts as a methyl donor in the process [13]. Betaine is the product of
the catabolism of choline [13]. Betaine methyltransferase is mainly present in the liver
and the kidney.
7

(7) 5,10 Methylenetetrahydrofolate Reductase (MTHFR): 5-methyltetrahydrofolate is
synthesized from 5,10-methylenetetrahydrofolate with the help of MTHFR [9]. This
NADPH-associated reduction process provides a methyl group for vital compounds such
as DNA and RNA and controls the folate coenzyme entry in the remethylation pathway
for Hcy metabolism [14].
(8). Cystathionine –synthase (CBS): L-cystathionine, the precursor for the synthesis of
Cys, is produced by the condensation of Hcy and serine [14]. This condensation is
expedited by CBS which is a cytosolic pyridoxal 5' phosphate-requiring enzyme. This
enzyme mainly occurs in human liver [14].
1.3. Hcy and human health
As described in the previous section, Hcy is the key intermediate in the Met and Cys
synthesis. Any alternation in these two metabolic pathways i.e. remethylation and
transsulfuration, may result in abnormal levels of Hcy. Elevated levels of Hcy are directly
linked to a number of pathologies mainly cardiovascular diseases [19], Alzheimer’s [20],
birth defects and pregnancy complications [21], osteoporosis[22], renal failure [23],
cancer [24], inflammatory bowel disease [25], and cancer[24]. Normal Hcy levels can be
disturbed by several factors such as a deficiency of enzymes involved in Hcy metabolism
(for example cystathionine –synthase (CBS), MTHFR, MS)[11], inadequacy of vitamin
B6, B12 and/or folic acid [2], overburdening of dietary methionine and buildup of
excessive reactive oxygen species (ROS) [3]. Other factors that affect Hcy homeostasis
include heavy smoking, caffeine and alcohol consumption, specific drugs, renal
dysfunction, life style, age and gender [26]. A deficiency of folate or defects in MTHFR
8

alter the formation of 5-methyltetrahydrofolate that results in lower concentrations of SAdoMet and overloading of Hcy for the transsulfuration pathway. Furthermore,
insufficient levels of S-AdoMet also suppress the transsulfuaration pathway, and this
overall process leads to the accumulation of excessive Hcy in the cells, followed by its
transfer to the blood stream producing hyperhomocysteinemia [11]. It is also caused by
defects in CBS, responsible for transsulfuration pathway, which forces Hcy to proceed
via remethylation to produce excess S-AdoMet. This eventually leads to feedback
inhibition of MTHFR impeding the remethylation process. This causes severe
hyperhomocysteinemia wherein the entire Hcy metabolism is impaired [11]. A number of
diseases associated with hyperhomocysteinemia are listed below.
Cardiovascular diseases (CVD)
Hcy has been established as an independent risk factor for cardiovascular diseases. A
number of published studies indicate the direct link between CVD and elevated levels of
Hcy [27-30]. According to an early study by WHO, CVD mortality rate and Hcy levels
are closely related to each other.
In 1969, McCully published a report about two patients, 2 months and 8 years
old,

with

homocystinuria.

Homocystinuria

is

a

form

of

very

severe

hyperhomocysteinimia wherein homocysteine overload leads to its excretion in urine.
McCully’s young patients suffered from premature atherosclerosis due to a deficiency of
CBS [31]. Since that time, a wide variety of studies have been published suggesting
modestly higher level of Hcy are a risk factor for atherosclerosis [32]. An association
9

between plasma Hcy and mortality rate was published by Refsum et al. Their study
revealed that the mortality rate was 24.7 % in CVDs patient with plasma Hcy >15μM
[19]. Recently, Tentolouris et al. indicated that acute Met-induced hperhomocysteinemia
affects myocardial performance and impairs aortic distensibility [27].
The occurrence of hyperhomocysteinemia is assessed to be 5% in the general
population and 13% to 47% among patients suffering from symptomatic atherosclerotic
vascular disease [26]. A meta-analysis of cross-sectional epidemiologic studies revealed
that a 60% higher occurrence of ischemic heart disease was noticed with increase in each
5 μM concentration level of plasma Hcy [33]. Cross-sectional studies and prospective
studies both confirm that the incidence of myocardial infarction was increased by 3.4 fold
when the concentration of Hcy was more than 16 μM. The mortality rates of CVD
patients was 4.5 fold higher at a Hcy concentration higher than 20 μM [34].
A multivariate analysis conducted by Boutouyrie et al. indicated that out of Hcy,
Cys and GSH, only Hcy was directly linked with carotid artery remodeling, suggesting
that Hcy is the only plasma thiols that acts as an independent risk factor for CVD [35].
Meta-analysis studies presented a correlation of plasma Hcy concentration with
ischaemic heart disease, deep vein thrombosis, pulmonary embolism and stroke [32].
Both genetic and prospective studies revealed lowering Hcy concentration by 3μM
reduced the risk of ischaemic heart diseases by 16%, deep vein thrombosis by 25 % and
stroke by 24 % [32]. Also, a prospective study conducted on women with a risk of
myocardial infarction found that fasting Hcy levels are positively related with myocardial
infarction risk in women [36].
10

Alzheimer’s disease (AD)
Hyperhomocysteinemia has been also considered to be an independent risk factor for
cognitive impairment, dementia and Alzheimer’s disease (AD) [20]. According to the
National Health and Nutrition Examination Survey (NHANES III), hyperhomocysteinem
ia is directly linked to weak memory in elderly people. A survey was conducted on
participants over 60 years of age. Participants with greater Hcy levels and lower folate
levels received a lower score on short delayed recall tests [37].
AD has been associated with an increased level of Hcy, along with a deficiency of
vitamin B6, B12 and folic acid [38]. Elevated levels of Hcy and S-AdoHcy deter the
remethylation processes of Met and S-AdoMet. This affects the methylation of various
vital components such as DNA and protein, eventually damaging the vascular structure,
neurotoxicity and causing apoptosis.
According to Lehman et al. unusual high levels of Hcy were found in patients
suffering from AD as compared to a control group [39]. Ueland et al. published a study
that presented considerably higher levels of Hcy along with a deficiency of folate and
vitamin B12 in the AD patients. It also revealed that slight increases in Hcy levels have a
strong effect on the risk of AD, and are 4.5 times greater in patients with Hcy
levels ≥14μM compared to patients with ≤ 11μM [40]. Another case study conducted at
the interval of 8 years on 1092 elderly patient stated that risk of AD was increased by
40% with 5 μM increases in Hcy concentrations, whereas risk was doubled at Hcy
concentrations ≥14μM [20].
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Neural tube defects (NTD)
It is well known that the intake of folic acid during pregnancy can reduce the risk of
neural tube birth defects. Levels of folate and vitamin B12 were found to be lower in the
women carrying fetuses with NTD than the women with normal fetuses [41]. However,
despite folate and vitamin B12 supplements, the risk of NTD remains elevated indicating
that other metabolic factors are also responsible for this defect [42]. A case study
reported by Scott et al. showed abnormal levels of Hcy present in the women with NTD
fetuses. According to the authors, the abnormal levels were related to the defects in the
enzyme methionine synthase [43]. This enzyme is necessary for methylation reaction
such as DNA and myelin a basic protein, which may be a possible mechanism for NTD.
Another factor responsible for NTD is the C677T and A1298C mutations in the
(MTHFR) gene [44]. This can be regulated by folate supplement. However MTHFR
polymorphism is a moderate risk factor for NDT in comparison to the methionine
synthase.
Osteoporosis
In a 2005 review Herrmann et al. described a direct link between osteoporosis and Hcy
levels. They explained that Hcy is not merely a risk indicator, it is also involved in bone
metabolism [22]. A study conducted by Mudd et al. shows that ‘bone mineral density’
(BMD) was found to be lower in patients suffering from homocystinuria. Moreover, a
risk of osteoporosis was found to be 50% by the age of 16 [45]. Studies conducted on
large populations revealed that increases in Hcy levels elevate the risk of fragile bone
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fractures [46, 47] Abnormal skeletal growth, skeletal deformities, an elongated
appendicular skeleton and flattening of the vertebral bodies have been observed in
homcystinuric patients [48-50]. According to a double-blind placebo-controlled
intervention trial conducted by Sato et al. “Hcy lowering therapy treatment (5 mg of
folate and 1500 g of vitamin B12) was found to be effective in reducing the hip fracture
rate in hemiplegic stroke patients [51]. The role of Hcy in osteoporosis is not clearly
understood. It is believed that Hcy can affect bone metabolism in different ways; for
instance, it can inhibit osteoblast formation and accelerate the osteoclast formation
thereby affecting bone resorption. It can also lead to decreased bone blood flow. It
inhibits collagen cross-linking, thereby reducing bone extracellular matrix (ECM) quality
[22].
In addition to the aforementioned disorders, Hcy has been linked to inflammatory
bowel disease [25], diabetes [52] and cancer [24].
1.3.1 Hcy: A biomarker or a risk factor!
Several clinical studies have successfully demonstrated a strong link between Hcy with
CVD [19]. However, it has been a subject of debate from decades, whether Hcy is merely
a biomarker or in fact a risk factor [53]. A proper mechanism for the role of Hcy in CVD
has not been clearly understood. The efficiency of folic acid supplementation in stroke
prevention was examined by a meta-analysis study [54]. The results indicated that folic
acid supplementation may effectively reduce the risk of stroke for the patient [54]. A
randomize controlled trial was conducted by Hess et al. on 553 patients to study the
effect of Hcy lowering therapy by a combined supplement of folic acid, vitamin B6 and
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B12. The results revealed that after percutaneous coronary intervention, the frequency of
major adverse events was substantially reduced [55]. Improvement in the stroke mortality
was also reported in a government study after folic acid fortification in United States and
Canada [56].
Nevertheless, another meta-analysis of randomized and controlled trial conducted
by Saver et al. showed that folic acid and vitamin B12 combined together provided a very
mild benefit to prevent primary stroke in male patient [57]. Similarly, McQueen et al.
investigated the efficacy of Hcy-lowering therapy on stroke risk, severity and disability.
Their 5 year study on 5522 adults with CVD demonstrated that a combined supplement
of folate and vitamin B decreased the frequency of overall stroke but stroke severity and
disability remained unaffected [58]. On the other hand, supplementation of vitamin B12
along with folate as Hcy-lowering therapy for secondary prevention in patients that
suffered from acute mycardinal infarction was published by Rasmussen et al. Their
investigation revealed Hcy-lowering therapy had no impact on the risk of recurring CVD
after myocardial infarction, in fact vitamin B12 had an adverse effect [59]. Similar cases
were reported by Ebbing et al. where secondary prevention by folic acid and vitamin B
supplementation in patients with coronary artery disease or aortic valve stenosis was
found to be ineffective on CVD and total mortality [60]. Possible reasons for the failure
of Hcy lowering therapy were explained by Blom et al. These include (1) the duration of
these trials and interventions were not long enough to decide whether Hcy lowering
therapy is helpful to prevent the risk of CVD. Most of these trials were conducted for less
than 5 years. Since atherosclerotic plaque develops 30-40 years from initial growth to
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clinical trials, Hcy lowering therapy may require a much longer period of trial than a
relatively few years of study[61]. Reason two is that the majority of interventions
understudied patients with greater levels of homocysteinimea (> 20μM), as mostly
patients with just slightly higher levels of Hcy were included in the trials. Reason 3 is that
the adverse effects of folate and vitamin B supplements were not taken into consideration
in aggravating CVD. Fourth, a better understanding of the role of Hcy in damaging the
vascular system is needed so that a proper study and treatment can be designed, apart
from folate and Vitamin B supplementation. A fifth reason given is that Hcy lowering
therapy was found to be ineffective because patients already had advanced CVD with a
vascular system so impaired that folate and vitamin B supplementation was insufficient
or too late to control the disease [61].
Regardless of whether Hcy is a biomarker or risk factor, a strong correlation
between Hcy and CVD as well as other diseases generates a great demand to determine
Hcy levels. Therefore, in this study, a method to detect Hcy has been developed.
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The main objectives of this project are:
1. Development of an optical method and design of a sensor for selective detection
of Hcy.
2. To detect Hcy at its physiological levels in addition to the elevated levels.
3. To achieve a selective response of Hcy in presence of other related potentially
interfering analytes, especially Cys, as well as in biological media.
This thesis has been divided into five chapters. After an introduction in the first chapter,
an overview of the current state of the art of techniques for Hcy detection is described in
the second chapter. The third chapter explains the development of a novel optical method
for the selective detection of Hcy using aldehyde bearing flurophores as sensors. In the
fourth chapter, the mechanism behind the selectivity for Hcy is described. The fifth
chapter includes the design and synthesis of a novel aldehyde bearing flurophore to
achieve a sensitive and selective fluorescent signal in response to Hcy at biologicallyrelevant concentrations.
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CHAPTER 2 AN OVERVIEW – TECHNIQUES INVOLVED IN HCY
DETECTION
2.1 Introduction
As describes in chapter one, elevated levels of Hcy are linked to a number of diseases,
especially cardiovascular diseases. The association of Hcy levels with such life
threatening diseases has generated a great interest in the scientific world to develop
different methodologies for detection of this biomarker[62]. For example, high
performance liquid chromatography (HPLC) [63-65], liquid chromatography/mass
spectroscopy (LCMS) [66, 67], electrochemical [68-70], enzymatic [71, 72], and
immunoassay [73] [72] and optical methods [74-79] have been employed to detect Hcy.
2.2 Existing methods for the detection of Hcy
In current diagnostic laboratories, techniques such as HPLC [80], LCMS [81], enzymatic
procedures [82-84], and immunoassays [85-87] are more prevalent for detection of Hcy.
Their popularity is due to the sensitive and precise measurements of Hcy. However, these
techniques also suffer from some disadvantages. For example, HPLC and UHPLC
involve an additional derivatization step with a suitable reagent, and also require
thorough sample preparation and labor intensive work with expensive instruments [2, 62,
88-90]. LC/MS involved complicated sample preparation methods and expensive
instruments [67, 91].
The first immunoassay method was developed by Shipchandler and Moore in
1995 [92]. tHcy is reduced to free Hcy by a suitable reducing agent. Next, Hcy is
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enzymatically transformed to S-adenosyl-Hcy (SAH) by the action of S-adenosyl-Hcy
hydrolase (SAHH). Anti SAH antibodies are used for the immunoassay of SAH via
different

techniques

such

as

fluorescence

polarization

immunoassay

(FPIA),

chemiluminescence immunoassay (ICL), enzyme-linked immunoassay (EIA), the
immune precipitation assay (IP) [93], For instance, Zappacosta et al. used anti-S-AdoHcy
antibodies bound to polystyrene particles to bind SAH [73]. SAH had to compete for
anti-SAH antibodies with thyroglobulin (TG) conjugated S-adenosyl-cysteine (SAC). The
presence of SAH caused a weaker aggregation of polystyrene particles. In absence of
SAH, TG-conjugated SAC induces a complete aggregation of polystyrene particles. The
signal is measured by the scattered light which is inversely associated to SAH content
[73]. However, the accuracy and adequate specificity of immunoassay techniques have
been questioned in the past [94-96]. These methods suffer from the interferences such as
effects of anticoagulants, icterus, hemolysis, lipemia, and sample storage [94, 95, 97].
Apart from that, analyte dependent interferences are produced by the interaction of
sample component with one or more antibodies such as human anti-animal antibodies,
auto-analyte, heterophilic antibodies, rheumatoid factor and other proteins [94, 95]. These
interferences may lead to false results.
In enzymatic procedures, cystathionine - β-synthase (CBS) was used to synthesize
cystathionine from Hcy and serine [71]. With the help of γ-cystathionase lyase,
cystathionine

was

converted

to Cys, ammonina

and

pyruvate.

Using

lactate

degydrogenase (LDA), the reduction of pyruvate was carried out along with the oxidation
of NADH to NAD. The oxidation of NADH is measured by the spectroscopic methods
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[71]. Immunoassays and enzymatic procedures also require fragile and relatively
expensive biological material such as antibodies and other biomolecules. Therefore, their
proper washing, handling and storage is necessary [2, 83]. Regardless of these
complications, enzymatic procedures are the more commonly used methods on the
clinical level compared to immunoassays, HPLC and LCMS. The requirements of small
amounts of reagents, less complicated procedures, sensitivity and high output make
enzymatic procedure a method of interest for Hcy detection for regular clinical
applications [71, 73, 83]. However, a comparative study of all these techniques for tHcy
determination shows imprecision and variations in the results [98].
2.3 Methods based on electrochemistry and nano materials
Other techniques for Hcy detection have been reported in the literature that includes, the
use of nano particles [99, 100] and electrochemical techniques[69, 88, 100, 101] etc.
Recently, a silica nanoparticle based sensor was reported by Wu et al. [102]. They
developed a mesoporus silica nanoparticle (MSN) based nanostructure as fluorescence
sensor for detection of Hcy. They prepared a fluorescence sensor by embedding the
anthracene nitroolefin inside the MSNs. In the absence of biothiols, the electron deficient
nitroolefin moiety quenches the fluorescence of electron rich anthrancene scaffold via
intramolecular charge transfer (ICT). Later, Michael addition of thiols to the nitoolefin
moiety prevents ICT, resulting in fluorescence enhancement. Thus the probe acts as a
fluorescence sensor for biological thiols. Selectivity for Hcy was achieved with the help
of covalently bound polyethylene glycol (PEG 5000) chains on the surface of the MSNs.
Based on the polarity and the size of the molecules, these chains serve as a barrier for the
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diffusion of different biological thiols inside the mesoporus nanoparticle. According to
them, relative lower content of polar groups and smaller size make Hcy best candidate
among all biological thiols, to pass through the barrier fastest and give a fluorescence
turn on signal by Michael addition reaction. However size and the polarity of Cys is
similar to that of Hcy but no explanation was given why Cys was not able to pass the
barrier. The sensor responded well towards Hcy, however equimolar concentrations of
other thiols such as Cys and GSH were used in the detection method. Therefore, Cys is
expected to cause interference at physiological levels, making the sensor ineffective for
specific responses to Hcy in plasma.

Scheme 2-1. Michael addition of Hcy on the nitroloefin moiety of 2.1 to prevent ITC that results in the
fluorescence of 2.2.

Yan et al. designed polyethyleneimine capped Ag-nanoclusters for Hcy detection
by resonance light scattering technique (RSL) [99]. Hcy served as a bridge between the
Ag core and polyethyleneimine (PEI) chains. This linking was due to the affinity of SH
group of Hcy for the Ag core and the ionic interaction of the carboxylate group of Hcy
with hyperbranched PEI chains. This resulted in the formation of a Ag-nanocluster
assembly. These nanoclusters interacted with one another to produce oscillation coupling,
enhancing the RSL signal. This assembly showed selectivity for Hcy over Cys and
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glutathione. However the instability of the Ag-particles makes it difficult to run the Hcy
assay in practice [103].
Several electrochemical detection techniques for Hcy detection have also been
reported in the literature [69, 88, 100, 101]. For example, Campton et al. achieved
responses for Hcy by an electrocatalytic reaction and 1,4 Michael addition of Hcy with
catechol using a modified carbon nanotube glassy carbon electrode (CNT–GCE) [68, 69].
Though the electrochemical detection of Hcy was carried out in the presence of Cys,
GSH and ascorbic acid using carbon electrode, the response for Hcy was not achieved at
a physiological level in the presence of other thiols and amino acids as well as in any
biological media [68].
Kerman et al. developed another electrochemical method wherein electrodepositi
on of gold on carbon nanotubes was employed for the enhanced electrochemical
detection of Hcy. They recorded the response of Hcy at very high concentrations (mM
level), and no information was given about other interfering thiols, amino acids and
biological media [100].
On the other hand, an amperometric Hcy biosensor array (HBA) was developed
by Ching et al. for the determination of Hcy. They fabricated amperometric HBA with a
D-amino acid oxidase (AAOx) immobilized on a screen printed carbon electrode[104].

Silver-silver chloride (Ag-AgCl) was used as a reference electrode. Detection sensitivity
was found to be the best with 8 working electrodes. Though this method was sensitive, it
involved several steps and was found to be time consuming. Moreover, they do not report
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the response of Cys and GHS, capable of undergoing the same oxidation mechanism as
Hcy, eventually causing interference with the response of Hcy. (Scheme 2-2)

Scheme 2-2. The enzymatic oxidation of homocysteine by D-amino acid oxidase to produce H2O2

2.4 Optical methods.
Optical methods have received a great deal of attention for the detection of biological
thiols [74-79]. The popularity of these methods is due to sensitivity, relative ease, and
low cost; however, to date there have been relatively few optical methods, especially
fluorescence methods, reported that can reliably distinguish Hcy over Cys, GSH and
other amino acids [105-110].
2.4.1 Optical detection based on the redox chemistry of Hcy
Our group has published a photochemical method for the detection of homocysteine in
whole plasma using viologens as redox based indicators [106, 107]. This mechanism, as
shown in Scheme 2-3, relies on the reduction of viologens by the α-amino carbon
centered radical of Hcy generated by intramolecular hydrogen atom transfer (HAT) of its
thiyl radical [106, 107]. Addition of Hcy to a solution of viologen resulted in change in
the absorbance spectra the viologen.
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Scheme 2-3. Mechanism for the detection of Hcy involving by generation of thiyl radical, hydrogen atom
transfer and reduction of BV2+

Lately, Wang et al. also published a redox based fluorometric detection of
homocysteine using a dansyl derivative as fluorescence probe [108] (Figure 2-1). The
selectivity for Hcy was proposed due to the oxidation of dansyl derivative probe DN-2 by
Hcy. Selectivity of the probe for Hcy over Cys was due to the formation of a favorable
five membered intermediate derived from Hcy, as opposed to the strained four membered
ring derived from Cys. They claimed the selectivity of Hcy over Cys and GSH,
nonetheless the response of Hcy in presence Cys and GSH towards the probe, had a
relatively very high fluorescence enhancement than the Hcy itself (almost two folds).
Under physiological conditions, where levels of Cys are 15-20 times higher than Hcy, it
would be confusing to decide whether the high response is from Hcy or Cys.
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Figure 2-1. Structure of desyl derivative probe DN-2

2.4.2 Methods for detection of Cys and Hcy based on Schiff base formation and
subsequent cyclization to form a heterocycle.
It is well know that, Cys and Hcy form thiazolidine and thiazinane heterocycles
upon reaction with aldehyde moiety (for more details refer chapter 4). Based on this
concept, some research groups have reported the detection of Hcy over Cys using
aldehyde bearing fluorophores [105, 109, 110]. Huang et al. reported a phosphorescence
sensor for Hcy detection based on an iridium (III) complex. Figure 2-2). Photoinduced
electron transfer (PET) from Cys-derived thiazolidine was believed to be responsible for
specificity of iridium (III) complex towards Hcy over Cys. Enhancement of the
photoluminescence upon addition of Hcy and quenching of the optical response with
respect to Cys was obtained. This complex produced a very good signal for Hcy,
nevertheless a response was achieved at a very high concentration (400 μM), far more
than the physiological levels, and the use of excess of DMSO (90%) as a reaction
medium makes it inapplicable in the biological sample.[109]
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Figure 2-2. Structure of phosphorescence sensor for Hcy based on iridium (III) complex, Ir(pba)2(acac)
(Hpba = 4-(2-pyridyl)-benzaldehyde; acac = acetylacetone)

Yoon et al. reported aldehyde bearing pyrene probes (P-Hcy-1 and P-Hcy-2) for
the selective detection of Hcy [105] (Figure 2-3). Addition of Hcy to a solution of pyrene
aldehdyes resulted in fluorescence enhancement. They stated that the distinct
fluorescence response of the probes towards Hcy and Cys was due to intramolecular
charge transfer (ICT) and photoinduced electron transfer (PET). However, the response
of Hcy at physiological levels in the presence of other interfering thiols was not reported.

Figure 2-3. Structures of P-Hcy-1 and P-Hcy-2.

Recently, an aldehyde bearing bodipy based turn on NIR fluorescent probe
containing a partially exposed aldehyde group at the meso position for the detection of
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Hcy over Cys was published [110] (Figure 2-4). At the equimolar concentration of Hcy
and Cys, after four hours, a 30 fold increase in the fluorescence was obtained for Hcy and
a 9 folds increase in the fluorescence for Cys was observed. Under physiological
conditions where Cys levels are 15-20 times higher than Hcy; hence, Cys will interfere
with the selectivity for Hcy. This makes the sensor unsuitable for Hcy detection in the
biological samples.

Figure 2-4. Structure of aldehyde bearing bodipy based sensor for Hcy detection

Keeping the above information in mind, it is safe to say that it has been very
challenging to design a molecule and develop a method which can deliver a distinctive
response to Hcy in the presence of other biological thiols and amino acids at
physiologically-relevant levels.
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CHAPTER 3 SELECTIVE DETECTION OF HCY USING FLUORESCEINE
ALDEHYDES
3.1 Background
It has been known for almost 90 years that Cys reacts with aldehydes and forms
thiazolidines [111]. Aldehyde-functionalized probes have received a great deal of
attention for the optical detection of aminothiols and amino acids [76-78, 105, 112-114]
First aldehyde-bearing fluorophore for the detection of Cys and Hcy was developed by
our group in 2004 [76]. These reactions are based on the well-known cyclization of the
aldehyde group with aminothiols to form thiazinane/thiazolidine heterocycles, as shown
in the Figure 3-1. The formation of these heterocycles affords a change in the electronic
properties of the chromophore and gives a different optical response than the molecule
itself.

Figure 3-1. General reaction scheme for reaction of carbonyl with Cys and Hcy

Interestingly, this class of probes has responded to their respective analytes via
either fluorescence quenching or fluorescence enhancement on a case by case basis. For
instance, Glass et al. reported the detection of amino acids using aldehyde bearing
27

coumarin probes, wherein the reaction of the aldehyde with amino acids to form imines
produced an enhancement of fluorescence [112]. Concurrently, Strongin and co-workers.
presented the detection of biological thiols with aldehyde bearing fluorophores [76, 77]
based upon the well-known reaction of aldehydes with N-terminal cysteine residues to
form heterocycilic thiazolidines [115] and N-terminal homocysteine residues to form
heterocyclic thiazinanes. They reported the fluorescence quenching of fluorescein
aldehyde probes due to the formation of thiazolidines/thiazinanes heterocycles, upon
reaction of Cys and Hcy [76]. Afterwards, several groups have implemented this concept
of aldehyde bearing probes for the detection of Cys and Hcy [75]. For instance, Kim
et al. observed the fluorescence quenching of an aldehyde bearing amino coumarin based
fluorophore in response to Cys/Hcy [113]. Hoang et al, reported an aldehyde bearing
hydroxy coumarin [114] in which addition of Cys/Hcy resulted in enhancement of the
fluorescence.
Another point of interest is that these aldehyde-based probes [76-78, 105, 112114, 116] have generally responded to the entire classes of analytes including amino
acids[112] or biological thiols [113, 114] without specificity for individual analytes
within each class. It is therefore of great interest and utility to develop a better
understanding of the mechanisms behind different signal transduction in these related
aldehyde-based probes. Such knowledge will lead to improved probes with increased
sensitivity for the selected aminothiols of interest, specifically for Hcy over Cys.
Besides understanding the mechanism of signal transduction for respective
analytes, it is equally important to focus on the difference in the spectroscopic responses
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of the probe itself and the probe-analyte complex with respect to excitation wavelength
(λex). In general, fluorescence responses of an analyte-indicator complexes are observed
at an excitation wavelength that corresponds to the absorption maximum of the dye or
indicator. However, the chosen excitation wavelength may not give the optimal response,
since it corresponds to the maximum absorption of the dye in the absence of analyte
[112]. In 2010, Strongin et al. had reported the optimum excitation wavelength for α,,β –
unsaturated aldehyde-based sensor for the detection of biological thiols, which was
different than the maximum absorption of sensor[78].
Usually, selective detection is obtained due to the specific and distinctive
interactions of analytes with sensors or receptors. However, different analytes or
biomolecules present in biological media may interact with the indicator through similar
supramolecular or covalent interactions. Therefore, the presence of these indicator-bound
species may interfere with the selective detection of the desired analyte. To overcome this
problem, Strongin et al. studied a simple approach for the selective detection of a target
biomolecule [117]. This new approach is based on the concept that the structural
differences among various complexes which were formed by the interaction of various
analytes with the same sensor may produce distinctive absorption and emission
responses. This potentially allows a multianalyte detection via a single optical indicator.
Based on this concept, a tunable detection of specific saccharides was achieved with the
help of the single optical indicator by the judicious selection of excitation and emission
wavelengths[117]. For instance, selective detection of fructose and ribose derivatives was
attained at different excitation and emission wavelengths as a function of time. A
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rhodamine boronic acid was used as an indicator in that study.
3.2 Mechanism of signal transaction in aldehyde bearing fluorophore probes upon
reaction with aminothiols
It is important to note the differences in the reaction of aldehyde-bearing probes with
aminothiols compared to amino acids. Amino acids react to form Schiff bases [112]
whereas, aminothiols such as Cys and Hcy react to form heterocyclic thiazolidines and
thiazinanes respectively [76]. These differences result in unique optical responses
towards aminothiols. The mechanism of signal transduction in fluorescein aldehyde
probes upon their reaction with aminothiols was investigated in this work.

Figure 3-2. Mechanism of signal transduction in generic aldehyde-bearing aminothiol probes.
(a) PET-based fluorescence quenching following reaction of Cys/Hcy with the aldehyde group. (b) PET
inhibition through hydrogen bonding between the amine-containing heterocycle and adjacent groups. (c)
PET inhibition through protonation of the amine-containing heterocycle.

There are several phenomena that impact the fluorescence response of aldehyde30

bearing probes. Figure 3-2 depicts the reaction of Cys/Hcy with the aldehyde group of a
generic aldehyde-bearing probe. The mechanistic understanding described herein, has led
to control over signal transduction in such a way that the probe can be tuned to respond to
Cys/Hcy through either quenching or enhancement. Importantly, the response can be
controlled in such a manner that Hcy is detected selectively over Cys.
It is well established that the free electrons of the amino group in the heterocycle
can quench the fluorescence of the probe (Figure 3-2a) through photo induced electron
transfer (PET) [113]. PET-induced responses have been modulated through tuning the
functionality of the fluorescent probes [118],[114]. For example, hydrogen bonding in
aqueous media between the amine-containing heterocycles and adjacent groups (Figure
3-2b) has been reported to inhibit PET leading to fluorescence enhancement upon
reaction with both Cys and Hcy with a coumarin aldehyde [114]. Conversely, PET
inhibition leading to selective fluorescence enhancement for Hcy/Cys can be achieved via
a mechanism involving protonation of the amino group of the heterocycle. (Figure 3-2c)
In this work, the above mentioned concepts were implemented based on the
structural differences between the complexes of fluorescein dialdehyde (FDA) or
/fluorescein monoaldehyde (FMA) with Cys and Hcy. Via different signal transduction
mechanisms, a specific response for Hcy was achieved by varying the excitation and
emission wavelengths as a function of time at specific pH values.
3.3 Previous work- response of fluorescein aldehydes to Cys and Hcy
Previously, in 2004, Strongin et al. investigated the reaction of 3.1(FMA), and 3.3 (FDA)
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with Cys and Hcy at pH 9.5 [76, 77]. As described below in Scheme 3-1 , this is a very
simple method for the detection of Cys or Hcy and doesn’t involve any complicated
biochemical techniques or preparative separation [76, 77]. This protocol was developed
on the same aforementioned concept i.e. the reaction of aldehyde with N- terminal Cys
residue to form thiazolidines [115, 119].

Scheme 3-1. Reaction of FMA (3.1) and FDA (3.3) with Cys and Hcy to generate thiazolidines/ thiazinanes
heterocycles respectively.

In Scheme 3-1, as shown above, the addition of Cys and Hcy to a solution of 3.3 results
in a change in solution color from yellow to orange. Optical studies have shown that the
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addition of Cys to the solution of 3.3 produces a red shift in the absorption spectrum from
480 nm to 495 nm which is shown in the Figure 3-3. Further, addition of Cys and Hcy to
a solution of 3.3 has also been shown to result in a monitorable fluorescence quenching
(excited at 460 nm) due to the formation of thiazolidines/thiazinanes as shown in Figure
3-4 and Figure 3-5. Moreover, NMR spectra proved the formation of thiazolidines/
thiazinanes in this reaction [76]. “Figure 3-3, Figure 3-4 and Figure 3-5 were adapted
with permission from [76] Copyright (2004) American Chemical Society."

Figure 3-3. Change in the absorbance spectra of 3.3 upon addition of Cys in buffer, pH 9.5 at room
temperature.
Each spectrum was acquired after 5 min. As the concentration of Cys increases, a red shift from 480 nm to
495 nm was observed.

Figure 3-4. Quenching of the fluorescence emission of 3.3 upon addition of Cys, excited at 460 nm, pH 9.5
at room temperature
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Figure 3-5. Quenching of the fluorescence emission of 3.3 upon addition of Hcy , excited at 460 nm , pH
9.5 at room temperature

In these optical studies, under basic conditions (at pH 9.5) both Cys and Hcy
displayed the same behavior towards 3.1 and 3.3 i.e. quenching of the fluorescence
emission of fluorescein aldehydes. This was attributed to the photoinduced electron
transfer (PET) of the lone pairs present on the nitrogen atom of heterocycles derived from
Cys and Hcy.
3.4 Present work – results and discussion
In the current study, the objective was to optimize the system to develop a simple,
convenient and inexpensive fluorescence method to serve as a sensitive analytical tool for
the detection of Hcy. It was hypothesized that at sufficiently low pH, the amine of the
heterocycles, which formed upon reaction with the probe, would be protonated, thereby
inhibiting PET and leading to florescence enhancement. Moreover, we anticipated that
the protonated amino groups in the thiazinane and thiazolidine would have different pKa
values due to hybridization differences as a function of ring sizes. Hence, it was decided
to study of response Hcy and Cys towards 3.1 and 3.3 at different pH values.
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The behavior of the reaction products was found to vary at different pH, as shown
in Figure 3-6, Figure 3-7 and Figure 3-8. At higher pH (9.5), Hcy and Cys both exhibited
expected quenching of the fluorescence of 3.1 as both retain their amine lone pairs. At
lower pH (5.5 and 6.0), Hcy enhanced the fluorescence of the fluorophore. However Cys
displayed fluorescence quenching (Figure 3-8) at pH 6.0 (at pH = 5.5 there was no signal
change). These results suggest that at pH = 6 the amine of the Hcy thiazinane was
protonated (PET quenching off) and that of the cysteine thiazolidine was neutral (lone
pairs retained and PET quenching on).
In the case of a 5-memebered Cys-derived thiazolidine ring, the C-N-C bond
angle is smaller than that in a 6-membered Hcy-derived thiazinane ring. This results in
greater % S-character of the N-H bond in the thiazolidines, rendering them less basic than
the thiazinanes[120-122]
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(b)

(a)

Figure 3-6. Optical sensing behavior of 3.1 towards Hcy and Cys at pH 9.5
(a) fluorescence spectral changes of 3.1 with Hcy and Cys after 30 min. (b) Time dependent fluorescence
spectral changes of 3.1 with Hcy and Cys. Solutions are composed of 4 µM of 3.1 with 1 mM of analyte in
carbonate buffer (100 mM, pH 9.5) DMSO 99:1 at 20 ºC, λex = 480 nm and λem = 515nm.

(a)

(b)

Figure 3-7. Optical sensing behavior of 3.1 towards Hcy and Cys at pH 5.5.
(a)fluorescence spectral changes of 3.1 with Hcy and Cys after 2h. (b) Time dependent fluorescence
spectral changes of 3.31 with Hcy and Cys. Solutions are composed of 4 µM of 3.1 with 1 mM of analyte
in phosphate buffer (100 mM, pH 5.5) DMSO 99:1 at 20 ºC, λex = 480 nm and λem = 515nm.
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(b)

(a)

Figure 3-8. Optical sensing behavior of 3.1 towards Hcy and Cys at pH 6.0.
(a) Fluorescence spectral changes of 3.1 with Hcy and Cys after 2h. (b) Time dependent fluorescence
spectral changes of 3.1 with Hcy and Cys. Solutions are composed of 4 µM of 3.1 with 1 mM of analyte in
phosphate buffer (100 mM, pH 6.0) DMSO 99:1 at 20 ºC, λex = 480 nm and λem = 515nm.

The hypothesis and results showed that lowering the pH of the reaction medium
results in the enhancement of the fluorescence of 3.1 in the presence of Hcy. After
studying the responses to thiols as a function of pH, a study was conducted to explore the
response of 3.1 towards Hcy and Cys at a different excitation wavelengths. It was again
hypothesize that the fluorescence response would be maximum when excited at
wavelength which is near the absorption maxima of the reaction product, instead of the
absorption maxima of the probe itself. Based on this concept, maximum response for the
detection of amino acids and Cys as well as tunable detection of saccharides[117] have
been reported in the literature [78, 112, 117]. Absorbance spectra of 3.1, show that the
addition of Hcy or Cys to a solution of 3.1, produces a red shift from 480 nm to 495 as a
result of the formation of thiazinane/thiazolidine heterocycles (
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Figure 3-9) [76].
To prove this second hypothesis, the optical response of Cys and Hcy towards 3.1
was monitored at higher excitation wavelengths, i.e. λex at 495 nm, near the absorption
maxima of the heterocyclic reaction product. On exciting at 495 nm, enhancement in the
fluorescence of 3.1 in response to Hcy was found to be 2 to 3 fold higher than the
excitation at lower wavelength (at 480 nm, lambda max of the probe itself) as shown in
Figure 3-10. Another interesting observation was that, on adjusting the pH from 5.5 to
6.0, the signal is modulated such that Hcy enhances the fluorescence of 1 while there is
minimal change upon reaction with Cys, as shown in Figure 3-11. These observations
led to a new method to achieve a maximum response of Hcy over Cys via adjusting the
pH of the reaction medium and the excitation wavelength. In the present case, the best
parameters are pH 6.0 and excitation wavelength, λex of 495nm.

(a)

(b)

Figure 3-9. Optical sensing behavior of 3.1 towards Hcy and Cys at pH 9.5.
(a) Time dependent absorption spectral changes of 3.1 with Hcy over 30 min. (b) Time dependent
absorption spectral changes of 3.1 with Cys over 30 min. Solutions are composed of 4 µM of 3.1 with 1
mM of analyte in carbonate buffer (100 mM, pH 9.5) DMSO 99:1 at 20 ºC
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(b)

(a)

Figure 3-10. Optical sensing behavior of 3.1 towards Hcy and Cys at pH 5.5.
(a) Fluorescence spectral changes of 3.1 with Hcy and Cys after 2h. (b) Time dependent fluorescence
spectral changes of 3.1 with Hcy and Cys. Solutions are composed of 4 µM of 3.1 with 1 mM of analyte in
phosphate buffer (100 mM, pH 5.5) DMSO 99:1 at 20 ºC, λex = 495 nm and λem = 515nm.

(a)

(b)

Figure 3-11. Optical sensing behavior of 3.1 towards Hcy and Cys at pH 6.0.
(a) Fluorescence spectral changes of 3.1 with Hcy and Cys after 2h. (b) Time dependent fluorescence
spectral changes of 3.1 with Hcy and Cys. Solutions are composed of 4 µM of 3.1 with 1 mM of analyte in
phosphate buffer (100 mM, pH 6.0) DMSO 99:1 at 20 ºC, λex = 495 nm and λem = 515nm.

The response of 3.1 towards GSH and various amino acids at pH 6.0 was also
investigated. As shown in the Figure 3-12, it was found that only Hcy promotes
fluorescence enhancement.
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Figure 3-12. Optical sensing behavior of 3.1 towards Cys and Hcy as compared to other biologically
relevant species.
Fluorescence response of 3.1 upon addition of different analytes (Cys, Hcy, GSH,Asn, Ala, Gln, Thr, Asp,
Arg, His, Glu, 1 mM). All Solutions are composed of 4 µM of 3.1 with 1 mM analyte in phosphate buffer
(100 mM, pH 6.0):DMSO 99:1 at 20 ºC, λex = 495nm λem = 515 nm

1

HNMR study of 3.1 in the presence of Hcy and Cys under these conditions also confirms

the formation of thiazinane and thiazolidine, upon reaction of Cys and Hcy with 3.1.
Figure 3-13 shows disappearance of aldehyde resonance at 10.39 ppm and appearance of
methine resonance at 6.81 ppm substantiate formation of these heterocycles. Whereas,
1

H NMR experiment of 3.1 with glycine shows the formation of a Schiff base (an imine ),

in the Figure 3-14, the Schiff base resonance at 9.11 ppm along with CHO resonance at
10.38 ppm shows the Schiff base formation was in equilibrium with the 3.1.
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Figure 3-13. H1 NMR of 3.1, 3.1 in the presence of Hcy (3 equiv) and 3.1 in presence of Cys (3 equiv) at
pH 6.0.
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Figure 3-14. H1 NMR of 3.1 and 3.1 in the presence of Gly (3 equiv) at pH 6.

Although highly selective for Hcy over Cys, 3.1 was not sensitive enough to produce an
appreciable response of Hcy at the lower levels. Therefore, it was decided to study the
response of Hcy and Cys towards 3.3, i.e. fluorescein dialdehdye.
The absorption spectra of 3.3 in the presence of Hcy and Cys are analogous to
those using 3.1, including a red shift in the absorption maxima upon addition of Hcy and
Cys from 480nm to 495 nm (Figure 3-15). Further, on exciting at a higher wavelength
(λex= 495 nm), 3.3 produces a >5 fold enhancement in the fluorescence upon addition of
Hcy (Figure 3-16). The signals using 3.3 were approximately twice as intense as from
3.1. The response of 3.3 towards Hcy was easily observed in as little as 15 min and
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plateaus near 45 min.

(a)

(b)

Figure 3-15. Optical sensing behavior of 3.3 towards Hcy and Cys at pH 6.0.
(a) Time dependent absorption spectral changes of 3.3 with Hcy over 2h. (b) Time dependent absorption
spectral changes of 3.3 with Cys over 2h. Solutions are composed of 4 µM of 3.3 with 1 mM of analyte in
Phosphate buffer (100 mM, pH 9.5) DMSO 99:1 at 20 ºC

(a)

(b)

Figure 3-16. Optical sensing behavior of 3.3 towards Hcy and Cys at pH 6.0.
(a) Fluorescence spectral changes of 3.3 with Hcy and Cys after 2h. (b) Time dependent fluorescence
spectral changes of 3.3 with Hcy and Cys. Solutions are composed of 4 µM of 3.3 with 1 mM of analyte in
phosphate buffer (100 mM, pH 6.0) DMSO 99:1 at 20 ºC, λex = 495 nm and λem = 515nm.

Having identified the optimal conditions for the discrimination of Hcy over Cys, the
response of the more sensitive dialdehyde 3.3 towards normal healthy concentrations of
aminothiols in pH 6.0 buffer was investigated. As shown in the Figure 3-17, No response
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was observed toward 250 M Cys, while 15 M Hcy resulted in a ~10% increase in the
fluorescence. The fluorescence response of 3.3 towards Hcy increased linearly with the
increase in the Hcy concentration, and the limit of detection was found to be as low as 2.5
M as shown in the Figure 3-18.

Figure 3-17. Optical sensing behavior of 3.3 towards Cys and Hcy at their biological concentrations at pH
6.0.
Fluorescence spectra of 3.3 with Cys and Hcy after two hours. Solutions are composed of 30 µM of 3.3
with 250 µM of Cys and 15 µM of Hcy in phosphate buffer (100 mM, pH 6.0):DMSO 99:1 at 20 oC, λex =
494 nm.

Figure 3-18. Spectral response of 3.3 towards increasing levels of Hcy in phosphate buffer (100 mM, pH
6.0).
Solutions are composed of 4 µM of 3.3 with 0-80 µM of Hcy in phosphate buffer (100 mM, pH
6.0):DMSO 99:1at 20 0C, λex = 494 nm and λem = 515 nm.
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The response of 3.3 in deproteinized plasma at elevated levels of Hcy was also
investigated. To measure a known amount of Hcy deproteinized plasma was spiked with
Hcy (100μM). Under this condition, 3.3 functioned well in the presence of spiked Hcy.
The response of physiological levels of Cys (i.e. 250 μM) towards 3.3 was insignificant
as shown in the Figure 3-19.

Figure 3-19. Optical sensing behavior of 3.3 towards Cys and Hcy in deproteinized bovine plasma at pH
6.0.
Solutions are composed of 25 µM of 3.3 with 250 µM of Cys and 100 µM of Hcy in phosphate buffer (100
mM, pH 6.0):DMSO 99:1 at 20 oC after 2 hr, λex = 495 nm.

3.5 Conclusion
In conclusion, the optimum conditions to attain the specific detection of Hcy via a
characteristic fluorescence increase with 3.1 and 3.3 were identified. Under basic
conditions, addition of Hcy and Cys to a solution of fluorescein aldehyde (3.1 or 3.3),
resulted in fluorescence quenching due to the PET from the lone pair of electron, present
on the nitrogen atom of heterocycles derived from Hcy and Cys. Whereas under acidic
conditions, protonation of amine of Hcy/Cys derived heterocycles inhibits PET and
produces fluorescence enhancement. pH 6.0 was found to be the optimal pH for the
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detection of Hcy, at this pH the response to Hcy of 3.1 and 3.3 led to fluorescence
enhancement, whereas the response to Cys was minimal.
Apart from the pH dependence, the detection of Hcy was also found to be
wavelength dependent. The magnitude of the response was at the maximum when excited
in the region near the absorption maxima of the analyte-probe complex (λex= 495nm)
rather than the absorption maxima of probe itself ( λex= 480nm). Fluorescein dialdehyde
(3.3) was found to be more sensitive than fluorescein mono aldehyde (3.1). The reaction
of 3.3 with Hcy resulted in more than a fivefold enhancement in fluorescence. 3.3 was
also found to function in deproteinized plasma, detecting relatively high levels of Hcy
(100 M).
3.6 Experimental section
3.6.1 Materials
All chemicals were purchased from Sigma Aldrich and used as received. Ultra-pure water
(18.2 MΩ·cm at 25 °C) obtained from a Milli-Q direct water purification system was
used to prepare all aqueous solutions. All spectroscopic measurements were carried out in
DMSO:buffer (1:99) solutions. 3.1 and 3.3 were synthesized from the procedure reported
in the literature based on the Reimer Tiemann reaction for formylation [77].
3.6.2 Methods
1

H-NMR spectra were recorded on an ARX-400 Advance Bruker spectrometer

performing at 400.13 MHz (1H). D2O:H2O (1:9) solvent system was used as NMR
solvent. All chemical shifts (δ) were reported in ppm using DSS (sodium 2,2-dimetyl-246

silapentane-5-sulfonate) as an internal standard (=0.000) for 1H-NMR studies.
3.6.3 Spectrophotometric measurement
UV-visible spectra were recorded on a Cary 50 UV-Vis spectrophotometer (Agilent
Technologies). Fluorescence spectra were obtained on a Cary Eclipse fluorescence
spectrophotometer (Agilent Technologies) with slit widths set at 5 nm for both excitation
and emission, respectively. Fluorescence spectra were corrected for the wavelength
dependent response of the R928 photomultiplier tube with the help of a manufacturer
generated correction file. All spectrophotometric measurements were conducted at room
temperature.
3.6.4 Deproteinization of plasma
Deproteinization of plasma was carried out by reconstituting the lyophilized bovine
plasma with ultrapure water to 1/3 of the reconstitution volume. Two equivalents of
acetonitrile (2/3 of the reconstitution volume) were added. This solution was vortexed for
10 min. after letting the solution stand for 10 minutes, it was centrifuged at 4000 RPM for
30 minutes to pellet the proteins. The decanted supernatant was aliquoted into sample
vials and re-lyophilized. The vials were then sealed and stored in a refrigerator (4 ºC).
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CHAPTER 4 MECHANISTIC STUDIES
4.1 Introduction
Fluorescence enhancement due to PET Inhibition is a well-known phenomenon. [123]
PET based fluorescence sensors have been widely used to detect an individual or a class
of analytes [109, 113, 114, 123-125]. This effect has been observed in the case of
fluorescein aldehydes. As seen in previous chapter, under acidic conditions, amine of
Hcy-Cys derived heterocycles is protonated causing inhibition of PET and fluorescence
enhancement. However, at an intermediate pH, the response of Hcy was observed but
Cys seems to give minimal or insignificant response.
4.2. Result and discussion
Here the objective was to understand the difference in the fluorescence response of Hcyderived thiazinane and Cys-derived thiazolidine which are formed upon reaction of Hcy
and Cys with 3.1 and 3.3 respectively. The difference in the response of Hcy than Cys
towards 3.1/3.3 was possibly due to the difference in the pKa value of protonated amine
of Hcy-derived thiazinane and the Cys-derived thiazolidine. Since, the C-N-C bond angle
for 5-memebered Cys-derived thiazolidine ring is smaller than the 6-membered Hcyderived thiazinane ring, it generates a greater S-character of the N-H bond in the
thiazolidines, making them less basic than the thiazinanes [120-122]. To prove this
hypothesis, it was necessary to understand the difference in the basicity of amine of
Hcy/Cys derived heterocycles. Previously, the basicity of the amine of thiazolidine-4caroboxylc acids has been studied [126-129] but the basicity of the amine of the Hcyderived thiazinane-4-carboxylic acids had not been reported. Therefore, a series of 548

and 6-membered 2-substituted thiazolidine/thiazinaneS-4-carboxylic acids were
synthesized as model compounds of 3.1 and 3.3.
4.2.1 Synthesis of Cys- and Hcy-derived analogs 4.1, 4.3, 4.5, 4.2, 4.4 and 4.6
To understand the difference in the basicity of 5- and 6-membered heterocyclic amines,
the Cys- and Hcy-derived analogs 4.1, 4.3, 4.5, 4.2, 4.4 and 4.6 were synthesized. 4.1, 4.3
and 4.5 were prepared by the reaction of Cys with salicylaldehyde, benzaldehyde and
formaldehyde respectively in aqueous medium at room temperature. Several attempts
were made for the synthesis of Hcy derived heterocycles analogs 4.2, 4.4 and 4.6.
Reaction of Hcy was carried out with salicylaldehyde, benzaldehyde and formaldehyde
respectively in aqueous and/or ethanol reaction medium by changing the number of
equivalents, water/EtOH ratio and time over a period of few hours to 3 days. 4.2 and 4.4
were obtained as colorless crystals from the reaction medium. However 4.6 remained
soluble in the aqueous medium therefore ethanol was added to the reaction mixture and
after 24 hours shiny colorless crystals of 4.6 were obtained.
4.2.1 Estimated pKa values of Cys- and Hcy-derived analogs 4.1, 4.3, 4.5, 4.2, 4.4
and 4.6
To confirm the hypothesis that the pH dependent Hcy enhancement was related to
the difference in the basicity of 5- and 6-membered heterocyclic amines, the estimated
pKa values of the protonated amine of the Cys- and Hcy-derived analogs were measured.
The values are reported in the Table 4.1. estimated pKa values were calculated from the
pH titration curves which are shown in Figure 4-1, Figure 4-2 and Figure 4-3. Cysderived 4.1, 4.3 and 4.5 are known [130, 131] and their previously published pKa values
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are in general agreement with those in Table 4.1. As seen in Table 4.1, the protonated
amine pKa of 6-membered thiazinanes is higher than that of 5-membered thiazolidines by
at least one unit. Therefore, based on the pKa of these analogs, we expect the protonated
amine pKa of Hcy-derived 3.2b to be approximately 1 unit greater (~6.7) than Cysderived 3.2a (~5.7). One unit difference in the pKa of amine of Hcy and Cys derived
heterocyles will affect the ionization state of amine at a given pH. For instance, at pH 6.0
major species for the amine of Hcy-derived thiazinane would exist mainly as the
ammonium ion whereas the amine of the Cys-derived thiazolidine would be at a nearly
equal concentration to the ammonium form.
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Table 4.1. Estimated pKa values of the protonated amine moiety of 2-substituted thiazolidine/thiazinane-4carboxylic acids.
Compound

pKa exp, (pKa lit)

Compound

pKa exp

NA,a (5. 67 [130])

6.67b

5.50,a (5.31[130])

6.85b

6.44, (6.19)

7.76

a

4.1 and 4.3 were found to be relatively unstable showing signs of decomposition in aqueous
solution during the course of the titration (Figure 4-1, Figure 4-2and Figure 4-4 ).
b
4.2 and 4.4 showed no indication of decomposition (Figure 4-1, Figure 4-2 and Figure 4-4 )
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(a)

(b)

Figure 4-1. Average of triplicates of (a) pH titration curve and (b) derivatives of 4.1 and 4.2
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(a)

(b)

Figure 4-2. Average of triplicates of (a) pH titration curve and (b) derivatives of 4.3 and 4.4
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(a)

(b)

Figure 4-3. Average of triplicates of (a) pH titration curve and (b) derivatives of 4.5 and 4.6

From the pH titration of thiazolidine-4-carboxylic acids, derivatives 4.1 and 4.3 were
found to be unstable in the aqueous solutions; however, thiazinane-4-carboxylic acids 4.2
and 4.4 appeared stable as shown in Figure 4-1 and Figure 4-2. Further, the stability of
thiazolidines/thiazinane-4-carboxylic acids 4.1 and 4.2 were studied by

1

HNMR

experiments. As shown in the , 1HNMR spectra of 4.1 and 4.2 were carried out in a
mixture of D2O:H2O (9:1). In the 1HNMR of 4.1, the appearance of an aldehyde
resonance at 9.88 ppm shows that 4.1 decomposes and goes back to starting material i.e
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salicylaldehyde. On the other hand 1HNMR of 4.2 doesn’t show any aldehyde proton
peak and the presence of a methine resonance at 5.7 ppm demonstrates the stability of
this compound in aqueous medium, as shown in Figure 4.4. The instability of
thiazolidine-4-carboxylic acids 4.1 and 4.3 in aqueous solutions has also been mentioned
previously[130] (particularly in strongly basic and acidic medium [132]).

Figure 4-4. 1H NMR of salicylaldehyde-Cys derived thiazolidines 4.1 and salicylaldehyde-Hcy derived
thiazinanes 4.2 in D2O:H2O

Table 1 and pH titration curves (Figure 4-1, Figure 4-2 and Figure 4-3) show the higher
basicity of the amine of the thiazinane-4-carboxylic acids than the amine of thiazolidine4-carboxylic acids at least by one unit. This difference in basicity results in the selectivity
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for Hcy over Cys. For the purpose of investigating the mechanism responsible for this
unique selectivity, first the simpler monoaldehyde 3.1 was studied. The response of 3.1
towards Hcy and Cys over a range of pH values was investigated (Figure 4-5). From the
pH dependent experiment, it is evident that, with a change in the pH values, the ratio of
amine to ammonium ion in the Hcy/Cys derived heterocycles changes. That eventually
affects the fluorescence response of 3.1 i.e. FMA (Figure 4-5). As the pH is lowered, the
percent of ammonium ion species increases, consequently the fluorescence enhancement
increases linearly as a result of PET inhibition by the ammonium ion. Due to the higher
pKa value of Hcy-derived thiazinane, there is a greater percent of ammonium ion species
in the solution than the Cys-derived thiazolidines.
At the appropriate pH, the ratio of ionization states of the amine moiety in
thiazolidine 3.2a would be such that fluorescence quenching by the lone pair electrons is
cancelled by PET inhibition from the ammonium species 3.2a' (Scheme 4-1). At this pH,
the amine group in thiazinane 3.2b exists predominately as the more fluorescent
ammonium 3.2b' (Scheme 4-1) because the pKa of 3.2b' is greater than that of 3.2a'. At
pH 6.0, the reaction between 3.1 and Cys does not result in a change in fluorescence
while reaction with Hcy results in fluorescence enhancement.

56

Scheme 4-1. Different ionization states of the the amine moieties in Cys- and Hcy-derived heterocycles at
pH 6.0.

Thus pH 6.0 is optimal for the detection of Hcy. Raising the pH increases the ratio of
amine to ammonium which leads to quenching, while decreasing the pH leads to
enhancement as clear from Figure 4-5.
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(a)

(b)
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(c)

(d)
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(e)

(f)

Figure 4-5. Time dependent fluorescence spectral changes and enhancement factor (inset) of fluorescence
of 3.1 with Cys and Hcy,(a) pH 5.5, (b) pH 6.0, (c) pH 6.5, (d) pH 7.0, (e) pH 7.4. (f) comparison of
fluorescence response of 3.1 towards Cys and Hcy at different pH.
Solutions are composed of 4 µM of 3.1 with 1 mM analyte in phosphate buffer (100 mM, pH 6.0):DMSO
99:1 at 20 ºC, λex = 495 nm and λem = 515 nm. For Time dependent fluorescence spectral changes, λex =495
and λem =515. Enhancement factor (EF) is the response of 3.1+ analyte divided by 1. When EF < 3.1
quenching is observed, while when EF > 3.1 enhancement is observed. The vertical line in the enhancement
factor plots is the experimentally determined optimal excitation wavelength of 495 nm. At pH 6.0 (b inset),
excitation at 495 results in enhancement for Hcy but no enhancement for Cys in response to 3.1.
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4.3 Conclusion
In conclusion, a new approach for the selective detection of Hcy using fluorescein
aldehyde-based probes has been developed. This method is based on intrinsic differences
between the pKa of 5- and 6-membered thiazolidines and thiazinanes formed upon
reaction with the aldehyde-bearing probes. At an optimum pH (6.0), amine of Hcyderived thiazinane is protonated to a greater extent (pKa~6.7) causing PET inhibition and
fluorescence enhancement. Due to lower pKa value (~ 5.7) of the protonated amine of the
Cys-derived thiazolidine, at pH 6.0, amine and ammonium ion species were seen in equal
quantity and therefore, no optical response was observed.
4.4 Experimental section
4.4.1 Materials
All chemicals were purchased from Sigma Aldrich and used as received. Ultrapure water
obtained from a Milli-Q direct water purification system was used to prepare all aqueous
solutions. All spectroscopic measurements were carried out in DMSO:buffer (1:99)
solutions. All experiments were performed at room temperature.
4.4.2 Methods
1

H NMR and

13

C NMR were recorded on an ARX-400 Advance Bruker spectrometer

performing at 400.13 MHz (1H) and 100.61 MHz (13C). All chemical shifts (δ) were
reported in ppm relative to DMSO-d6 (2.50 ppm, 1H; 39.52 ppm,

13

C) unless otherwise

indicated. For the study of stability of 4.1 and 4.3 in aqueous media, 1H NMR experiment
was conducted in H2O : D2O mixture (9:1) using DSS (sodium 2, 2-dimetyl-261

silapentane-5-sulfonate) as an internal standard (=0.000). ESI-HRMS (high resolution
mass spectrometry) were recorded at the PSU Bioanalytical Mass Spectrometry Facility
on a ThermoElectron LTQ-Orbitrap high resolution mass spectrometer. IR spectrum was
obtained by Fourier transform infrared (FT-IR) spectroscopy operated on a Thermo
Scientific Nicolet iS10 spectrophotometer equipped with a single-bounce diamond ATR
attachment.
4.4.3 Spectrophotometric measurement
Fluorescence spectra were obtained on a Cary Eclipse fluorescence spectrophotometer
(Agilent Technologies) with slit widths set at 5 nm for both excitation and emission,
respectively. Fluorescence spectra were corrected for the wavelength dependent response
of the R928 photomultiplier tube with the help of a manufacturer generated correction
file.
4.4.4 pKa measurements
pKa values of the amine of 2-substituted thiazolidines/thiazinaneS-4-carboxylic acids,
4.1, 4.3, 4.5, 4.2, 4.4, and 4.6 were obtained by the titration of their aqueous solutions
with 0.01M NaOH by following the procedure reported in the literature [126]. In the case
of 4.1 and 4.2, 0.1 M NaOH was used. The pH measurements were conducted using an
Orion 410A pH meter, which was standardized with Scientific Products potassium
hydrogen phthalate pH 4.00 buffer, BDH pH 7.00 and Scientific Products boric
acid/potassium hydroxide pH 10.00 buffer. All pH titrations were conducted in triplicates
and their average was reported.
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4.4.5 Synthesis of compounds 4.1, 4.2, 4.3, 4.4, 4.5 and 4.6
Scheme 4-1. Synthetic route of 4.1, 4.3 and 4.5

Scheme 4-2. Synthetic route of 4.2, 4.4 and 4.6

(2S,4R) and (2R,4R)-2-(2-hydroxy phenyl) thiazolidine-4-carboxylic acid (4.1)
L-Cys (1.67 mmol) and salicylaldehyde (1.67 mmol) were added in 5 mL of DI H2O.

Reaction mixture was stirred at RT for 2 h. The precipitates from the reaction mixture
were filtered, washed with ice cold H2O and dried under vacuum to yield 4.1 as a
mixture of distereoisomers, colourless solid (307 mg, 83%); max (film)/cm1 1738 (C= O)
; M.P.180-181°C; 1H NMR (400 MHz, DMSO) δ 7.49 (m, 1H, Ar), 7. (m, 1H, Ar), 6.91
(m, 2H, Ar), 5.84 (s, 1H, Ar-CH), 5.65 (s, 1H, Ar-CH), 4.26

(m, 1H, NH-

CH), 3.82 (m,1H, S˗CH2), 3.11 (m, 1H, S˗ CH2); 13C NMR (101 MHz, DMSO) 172.9˗
172.4 ( C=O), 155.1, 154.5, 129.00, 128.2, 126.00, 124.2, 119.00, 118.7, 115.6, 115.00,
67.6, 66.6, 63.2 , 38.00, 37.00; Electrospray ionization (ESI) mass spectrometry (positive
electron ionization) m/z :226.05602 ([M+H]+,100%), calculated for C10H11NO3S, m/z
:225.04596.
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(2S,4S) and (2R,4S)-2-(2-hydroxyphenyl)-1,3-thiazinane-4-carboxylic acid (4.2)
L-Hcy (1.88 mmol) and salicylaldehyde (1.88 mmol) were added in a mixture of 6 mL of

distilled water and 0.25 mL of ethanol. Reaction mixture was stirred at RT for 48 hrs.
The resultant precipitates were filtered, washed with ice cold H2O and dried under
vacuum to yield 4.2 as a mixture of distereoisomers, colourless solid.
(322 mg, 82%); max (film)/cm1 1738 (C=O); M.P.131-132°C;

1

H-NMR

(400

MHz,

DMSO-d6); δ (ppm): 7.35 (m, 1H, Ar), 7.15 (m, 1H, Ar), 6.87 (m, 2H, Ar), 5.43 (s, 1H,
Ar-CH), 3.59 (m, 1H, COCH), 3.22 (m, Hz, 1H, S-CH2), 2.89 (m, 1H, S-CH2), 2.08 (m,
1H, CH-CH2), 1.50 (m,1H, CH-CH2); 13C-NMR (101 MHz, DMSO) 173.49(C=O),
155.2, 154.1, 128.7, 127.8, 126.4, 125.8, 125.8, 118.9, 115.6, 59.3, 56.1, 54.8, 54.50, 28.7
7, 27.9, 26.4, 25.3 ; Electrospray ionization (ESI) mass spectrometry (positive electron io
nization) m/z : 240.07 182 ([M+H]+,100%), calculated for C11H13NO3S, m/z 239.06161.
(2S,4R) and (2R,4R)-2-phenylthiazolidine-4-carboxylic acid (4.3)
The synthesis of compound 4.3 has been reported in the literature [133]. Here an
improved and simpler procedure has been used for its synthesis. Compound 4.3 was
prepared according to the procedure described for 4.1. L-Cys (1.67 mmol) and (1.67
mmol) benzaldehyde were added in 5 mL of DI H2O. Reaction mixture was stirred at RT
for 2 h. The precipitates from the reaction mixture were filtered, washed with ice cold
H2O and dried under vacuum. Compound 4.3 was obtained as a mixture of distereoisome
rs, colourless solid (488 mg, 99%); max (film)/cm1 1668 (C=O); M.P.175-176 °C;
1

HMNR resonance for the major isomer are shown here, 1H-NMR (400 MHz, DMSO64

d6) δ (ppm) 7.4 (m, 5H, Ar) 5.67 (s, 1H, Ar-CH), 4.24 (q, 3JH-H = 5 Hz, 1H, CO-CH),
3.80 (m,1H, CH-CH2), 3.15 (m, 1H, CH-CH2) ; 13CNMR (101 MHz, DMSO-d6)

(ppm)

172.95, 172.19 (C=O), 141.18, 139.91, 128.31, 127.25, 127.57,126.91, 71.73, 71.06, 654
0, 64.85, 38.39, 37.94; Electrospray ionization (ESI) mass spectrometry (positive electro
n ionization) m/z : 210.06017 ([M+H]+,100%), calculated for C10H11NO2S, m/z
209.05105.
(2S,4S) and (2R,4S) -2-phenyl-1,3-thiazinane-4-carboxylic acid (4.4)
L-Hcy (1.88 mmol) and benzaldehyde (1.88 mmol) were added in 6 mL of DI water.

Reaction mixture was stirred at RT for 72 hrs. The resultant precipitates were filtered
washed with ice cold H2O and dried under vacuum. Compound 4.4 was obtained as a
mixture of distereoisomers, colorless solid (273 mg, 65%); max (film)/cm1 1738 (C=O);
M.P.177-178°C; 1H-NMR (400 MHz, DMSO-d6) δ (ppm) 7.55 (m, 5H, Ar), 5.27 (s, 1H,
Ar-CH), 3.60 (dd,

3

JH-H = 9, 3 Hz, 1H, CO-CH ), 3.28 (td,

3

JH-H = 11, 3 Hz

1H, S˗CH2,), 2.91 (dt, 3JH˗H = 10, 4 Hz, 1H, S˗CH2,), 2.10 (dq, 3JH˗H =7.0, 3 Hz, 1H, CH˗
CH2), 1.51 (qd, 3JH˗H = 9, 4 Hz, 1H,CH˗CH2); 13CNMR, (101 MHz, DMSO d6) δ(ppm)
173.5 (C=O), 140.8, 128.3 (overlapping), 127.8, 126.5, 64.1, 59.2, 28.9, 27.7; Electrospr
ay ionization (ESI) mass spectrometry (positive electron ionization) m/z :224.07707 ([M+
H]+,100%) calculated for C11H13NO2S, m/z 223.06670.
(R)-thiazolidine-4-carboxylic acid (4.5)
Synthesis of compound 4.5 has been reported in the literature, but for this work a
modified and simpler procedure was used [126, 127]. Compound 4.5 was prepared by
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following the procedure described for 4.1. Formaldehyde was used as the starting
material instead of salicylaldehyde. Compound 4.5 was obtained as a mixture of distereoi
somers, colourless solid. (152 mg, 68.5%). max (film)/cm1 1617 (C=O); M.P.181˗182°C;
1

H NMR (400 MHz, D2O) δ 4.52 (m, 1H CO CH and 2H, NH2CH2), 3.47 (m, 2H,

CH˗CH2).13CNMR (101 MHz, D2O) δ (ppm) 171.9 (C =O), 63.9, 48.6, 32.9.Electrospray
ionization (ESI) mass spectrometry (positive electron ionization) m/z : 134.0252 ([M+H]
+

,100%), calculated for C4H7NO2S, m/z 133.01975.

(S)-1,3-thiazinane-4-carboxylic acid (4.6)
The synthesis of compound 4.6 has been reported in the literature [134]. Herein, a
modified procedure to synthesize 4.6 has been used for the synthesis. L-Hcy (1.67 mmol)
and formaldehyde (1.67 mmol) were added in 6 mL of DI water. The reaction mixture
was stirred at RT for 48 h. The precipitates from the reaction mixture were filtered.
Ethanol was added to the filtrate. The solution was kept at RT for 24 hrs. Transparent
shiny crystal formation in the filtrate was observed. Crystals were filtered, washed with
ice cold ethanol and dried under vacuum to yield 4.6 as colorless shiny crystals (135mg,
55%) 1H NMR (400 MHz, D2O) δ 4.29 (m, 2H, NH-CH2-S), 3.68 (dd, 3JH-H = 10, 3 Hz,
1H, CO-CH), 3.05 (m, 1H, S-CH2-CH2), 2.89 (m,1H, S-CH2˗CH2), 2.56 (m, 1H, CHCH2), 2.04 (qd, 3JH˗H = 10, 3 Hz, 1H, CHCH2); 13CNMR (101 MHZ, D2O) 173.3
(C=O), 59.4, 45.1, 28.1, 26.0; Electrospray ionization (ESI) mass spectrometry (positive
electron ionization) m/z : 148.04422 ([M+H]+,100%), calculated for C5H9NO2S, m/z
147.03540.
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CHAPTER 5 SYNTHESIS OF FLUORESCEIN TRI ALDEHDYE AND ITS
APPLICATION IN THE DETECTION OF HCY
5.1 Introduction
In previous chapters, optimum conditions for the detection of Hcy using 3.1 (FMA) and
3.3 (FDA) have been discussed. The mechanism behind this selectivity is based on
differences in the basicity of Hcy and Cys derived heterocycles was also described. Based
on this mechanism, the next goal was to design a more sensitive aldehyde-bearing
fluorophore that can detect Hcy at its physiological levels in biological media.
Compounds 3.1 and 3.3 didn’t exhibit an sufficiently low detection limit for an
appreciable response from Hcy at concentrations below ~50 M in plasma (Figure 3-17).
To achieve this goal fluorophore reactivity was increased by adding another reactive
moiety and rendering the fluorophore ring more electrophilic. To implement this plan, it
was decided to increase the number of aldehyde moieties on the fluorescein scaffold. As
noticed before, the sensitivity of 3.3 was found to be twice of the sensitivity of 3.1.
Therefore it seemed reasonable that to improve the sensitivity of fluorophore, the number
of aldehyde moieties should be increased. Based on this concept, fluorophore, fluorescein
trialdehyde was designed.
5.2 Duff reaction and its application
Several methods have been reported in the literature for the formylation of aromatic
compounds [135, 136]. For example, the Riemer Tiemann reaction [137], Gatterman
reaction, Gattermann-Koch reaction [138], Vilsmeier-Haack reaction [139], and Duff
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reaction [140] are well known name reactions for the formylation of aromatic
compounds. The Riemer Tiemann reaction was applied towards the synthesis of 3.1 and
3.2. Both were obtained from the same reaction via a separation, unlike the long synthesis
reported by Lippard et al. [141] where at first, 4,5-dimethyl fluorescein was synthesized
from the reaction of 2-methyl resorcinol and phthalic anhydride, later hydroxyl groups of
4,5-dimethyl fluorescein were protected with the help of benzoic anhydride. In the next
step, Bromination of 4,5-dimethyl groups was carried out over a period of more than 7
days. Finally, bromo-methyl groups were converted to aldehyde groups by Swern
oxidation to yield 3.2 with 36% yield [141].
To synthesize fluorescein trialdehyde, a new synthetic strategy was used for the
diformylation of the phenolic ring. Previously, ortho (to a hydroxyl) diformylation using
The Duff reaction had been published [142] by Grylo et al. using a diverse range of
phenols as shown in Scheme 5-1. The Duff reaction also has some advantages including
relative simplicity and inexpensive, stable and relatively nontoxic reagents.

Scheme 5-1. Duff formylation of phenol

In 1934, An English scientist James Cooper Duff found that the reaction of
hexamethylenetetramine with phenolic compound in acetic acid yielded a Schiff base,
which upon hydrolysis in acidic medium, resulted in the ortho formyl product [143, 144].
68

Since then The Duff reaction has been utilized for the direct diformylation of aromatic
compounds in the synthesis of various drugs [145, 146], sensors [147, 148], and receptors
[149] with some modifications. In the present work, the main focus was on the first
application of The Duff reaction for the formylation of fluorescein to produce fluorescein
trialdehyde. Attempts for the Synthesis of fluorescein tetra aldehyde were also made.
5.3 Result and discussion
Under The Duff reaction conditions, formylation of commercially available fluorescein
was carried out by the reaction of fluorescein with hexamethylenetetramine in
trifluoroacetic acid under an inert atmosphere followed by acid hydrolysis to afford 5.1
i.e. fluorescein tri aldehyde (FTA) in a single step (Scheme 5.2)

Scheme 5-2. Synthesis of fluorescein tri aldehyde (5.1)

Fluorescein tri aldehyde was obtained in 2% yield. The reason for the small yield was
that, with the insertion of electron withdrawing aldehyde group in the fluorescein scaffold
the nucleophilicity of the fluorophore decreases. Therefore the reactivity of the molecule
towards electrophilic aromatic substitution for further formylation also reduces. As a
result small yield of 5.1 was obtained and fluorescein tetra aldehyde could not be
synthesized. Synthesis of 5.1, under The Duff reaction was attempted several times by
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changing the number of equivalents of reactants and duration of the reaction. It was
found that the ratio of fluorescein to HMTA (1:10 eqv) and duration of reaction i.e.72 hrs
were the best parameters to synthesize 5.1.
Before the application of The Duff reaction, for the synthesis of fluorescein tri
and tetra aldehyde, different reaction routes were also implemented. Formylation of tetra
bromo fluorescein in THF with butyl lithium and DMF under various reaction conditions
did not yield the desired product. formylation of tetra bromo fluorescein by isopropyl
bromide and DMF under different reaction conditions did not produce 5.1 either. Later,
hydroxyl groups of tetra bromofluorescein were protected by benzoyl chloride . OHprotected tetra bromofluorescein was subjected to formylation by isopropyl bromide and
DMF. However this reaction did not succeed to give desired product. Finally, phosphoryl
chloride and DMF were used for the formylation of fluorescein under a number of
different reaction conditions but none of them could produce formylated product.
Study of response of Hcy and Cys towards 5.1
To examine the sensitivity of this newly synthesized fluorophore 5.1, the reaction of Hcy
and Cys with 5.1 was studied at pH 6.0 (Figure 5-1). As expected, in response to Hcy, a
high fluorescence enhancement (~7 fold) was observed, whereas Cys didn’t show any
appreciable change in the fluorescence. Later, the magnitude of the response towards Hcy
with 3.1 and 3.3 (i.e. FMA and FDA) was also compared. The magnitude of fluorescence
response of 5.1 towards Hcy was found to be more than higher than that of 3.1 and 3.3
(Figure 5-2).
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(a)

(b)

Figure 5-1. Optical sensing behavior of 5.1 towards Hcy and Cys at pH 6.0.
(a) Fluorescence spectral changes of 5.1 with Hcy and Cys after 2h. (b) Time dependent fluorescence
spectral changes of 5.1 with Hcy and Cys. Solutions are composed of 4 µM of 5.1 with 1 mM of analyte in
phosphate buffer (100 mM, pH 6.0) DMSO 99:1 at 20 ºC, λex = 495 nm and λem = 595nm.
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(a)

(b)

(c)

Figure 5-2. Comparison of magnitude of response of Hcy towards (a) 5.1, (b) 3.3, (c) 3.1.
Solutions are composed of 4 µM of probe with 1 mM of analyte in phosphate buffer (100 mM, pH 6.0)
DMSO 99:1 at 20 ºC, λex = 495 nm and λem = 515nm

After investigating the relative magnitude of the signal in the detection of Hcy
with 5.1, its behavior towards Hcy and Cys was evaluated at physiologically relevant
levels. On adding Hcy (15 M) in the presence of Cys (250 M) to a solution of 5.1, an
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enhancement in the fluorescence (~1.5 fold) was obtained. Cys at 250 M does not
produce a change in the optical response of 5.1., as shown in the Figure 5-3.

(a)

(b)

Figure 5-3. Optical sensing behavior of 5.1 towards Cys and Hcy at their biological concentrations at pH
6.0.
(a) Fluorescence spectra of 5.1 with Cys and Hcy after two hours. Solutions are composed of 30 µM of 3.3
with 250 µM of Cys and 15 µM of Hcy in phosphate buffer (100 mM, pH 6.0):DMSO 99:1 at 20 oC, λex =
494 nm and λem = 525 nm.

The response to Hcy was also investigated in the presence of various amino acids
(Gly, Ala, Met, Gln, Glu, and Asp) along with Cys. Figure 5-4 shows that Hcy produces a
distinct response in the presence of these related amino acid analytes. Other amino acids
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and Cys produced a very small quenching in the fluorescence of 5.1. Whereas, Hcy
produced almost 3 folds enhancement in the fluorescence. That shows the specificity of
Hcy over other amino acids and Cys towards 5.1. Glutathione (GSH) produced no
significant

change

in

the

fluorescence

signal

(Figure

5-4).

Overall,

these

results demonstrated that 5.1 exhibited a distinct selectivity for Hcy.

Figure 5-4. Optical sensing behavior of 5.1 towards Hcy and Cys with and without amino acids and GSH
at pH 6.0
fluorescence emission of 1 with Cys and Hcy in presence and absence of amino acids and GSH after 2h.
Solutions are composed of 4 µM of 5.1 with 50 µM of each analyte in phosphate buffer (100 mM, pH
6.0):DMSO 99:1 at 20 oC, λex = 495 nm
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(a)

(b)

Figure 5-5. (a) and (b)- Spectral response of 5.1 towards increasing levels of Hcy in phosphate buffer (100
mM, pH 6.0 at 2h).
Solutions are composed of 4 µM of 5.1 with 0-25 µM of Hcy in phosphate buffer (100 mM, pH
6.0):DMSO 99:1at 20 0C, λex = 495 nm and λex = 525 nm

A concentration dependent experiment was also performed which indicated that
the fluorescence response of 5.1 increased linearly with a limit of detection at 1.88 M as
shown in Figure 5-5. LOD was calculated with the help of standard error, slope and
intercept from the calibration curve graph. Standard error was obtained from the
regression analysis in Microsoft Excel 2010.
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Further, at the physiological levels of thiols, the response of 5.1 towards Hcy and
Cys was investigated in deproteinized plasma. Results show that probe 5.1 was also
capable of detecting Hcy in biological media. To measure the known amount of Hcy,
deproteinized plasma was spiked with the known concentration of Hcy. In deproteinized
plasma, addition of Hcy to a solution of 5.1 enhances the fluorescence. In contrast, no
significant change in the emission intensity was observed upon addition of Cys. (Figure
5-6) With an increase in the concentration of Hcy, increase in the fluorescence emission
was also observed in deproteinized plasma, as shown in Figure 5-7.

Figure 5-6. Optical sensing behavior of 5.1 towards Cys and Hcy in deproteinized plasma at pH 6.0.after
2h.
Solutions are composed of 20 µM of 5.1 with 250 µM of Cys and 15 µM of Hcy in phosphate buffer (100
mM, pH 6.0):DMSO 99:1 at 20 oC, λex = 495 nm
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Figure 5-7. Optical sensing behavior of 5.1 towards Cys and Hcy in deproteinized plasma at pH 6.0.after
2h.
Solutions are composed of 20 µM of 5.1 with 5,10, 15, 20 and 25 µM of Hcy in phosphate buffer (100 mM,
pH 6.0):DMSO 99:1 at 20 oC, λex = 495 nm

As previously explained fluorescence enhancement of 5.1 by the addition of Hcy
was due to the formation of thiazinane-4-carboxylic acid, and subsequent protonation of
the amine, producing an ammnonium species at pH 6.0 to inhibit PET. To confirm the
PET inhibition based response of Hcy to 5.1, the reaction of Hcy and Cys was studied at
lower pH (5.0), intermediate pH (6.0) and higher pH (9.5). In Figure 5-8, it is evident that
at lower pH (5.0), the thiazinane and thiazolidines are in the ammonium form, since
fluorescent enhancement occurs. Conversely, at pH 6.0, the ammonium of the thiazinane
is the predominant species in contrast to Cys-derived thiazolidine, wherein the
ammonium and amine species exist in nearly equal amounts. At higher pH (9.5), the
amine of both heterocycles have their lone pairs available for PET quenching.
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(a)

(b)

(c)

Figure 5-8. Optical sensing behavior of 5.1 towards Cys and Hcy in buffer at different pH, after 2h.
Fluorescence spectra of 5.1 with Cys and Hcy (a) at pH 5.5 in phosphate buffer, (b) at pH 6.0 in phosphate
buffer, (c) at pH 9.5 in carbonate buffer .Solutions are composed of 4 µM of 5.1 with 1 mM of analyte in
100 mM buffer solution: DMSO( 99:1) at 20 oC, λex = 495 nm

Apart from being selective, the enhanced sensitivity of the probe 5.1 is due to the
presence of three electron withdrawing aldehyde groups that makes the fluorophore
scaffold more electrophilic and reactive. Previously, Huang et al. calculated the surface
charges based on density functional theory (DFT) for an aldehyde-bearing iridium (III)
complex. They found that charges on the N and S atoms of thiazolidine are more negative
than the charges on the N and S atoms of thiazinane. According to them, higher negative
charges on the thiazolidine can result in an intramolecular electron-transfer process from
the thiazolidine group to the excited complex, causing a weak photoluminescence of the
probe-Cys complex [109].
In the current case, as shown in Table 5.1, the Mulliken charges on the N and S
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atoms for Cys-derived thiazolidine are more negative ( N,-0.650223 and S,-0.384138)
when compared to the N and S atoms of Hcy-derived thiazinane (N,-0.399059 and S,0.078137). This is in agreement with the results reported by Huang et al. for the
intramolecular electron transfer process from the thiazolidine group resulting in
fluorescence quenching or weak enhancement [109].
Table 5.1 Comparison Mulliken charges on the ‘N’ and ‘S’ of Cys and Hcy derived heterocycles formed
upon reaction with 5.1

Mulliken charges Mulliken charges
5.1+Hcy‘N’-0.202843,
‘S’-0.020108,
-0.194407,
- 0.043911,
-0.209806
-0.059903
5.1+Cys ‘N’-0.542689,
‘S’-0.136779,
-0.544021,
-0.218184,
-0.529787
-0.358607

Further, the selective signaling for Hcy in terms of ionic charges can also be
explained. From the Mulliken charge calculations, it was found that the phenolate anion
and the ether oxygen of the thiazinane (Hcy)-dye adduct bear higher negative charges (0.729, - 0.686 and -0.326, respectively) than of the Cys-derived thiazolidine (-0.508, 0.621 and -0.280, respectively) and 5.1 (-0.659, -0.576 and -0.261, respectively, Table
5.2 and Figure 5-9). The development of enhanced negative charge density on the
fluorophore phenolate oxygen upon formation of the Hcy-derived thiazinane results in an
increase in fluorescence emission.
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Figure 5-9. Predominant species of compounds 5.1, 5.1a and 5.1b at pH 6.0. Calculated Mulliken charges
are shown for the oxygen atoms in the fused ring system.
Table 5.2 Comparison Mulliken charges on the phenolate ‘O’ and ether ‘O’ of 5.1 and Cys and Hcy
derived heterocycles formed upon reaction with 5.1

Mulliken charges
5.1

Phenolate oxygen,
ether oxygen

-0.65882, -0.575738,
-0.261133

5.1+Hcy Phenolate oxygen,
ether oxygen

-0.729433, -0.686371,
-0.325709

5.1+Cys Phenolate oxygen,
ether oxygen

-0.508089, -0.620732,
-0.280251

5.5 Conclusion
In conclusion, a highly selective fluorescein trialdehyde for the detection of Hcy at its
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physiological level in biological media has been developed. At pH 6.0, protonation of the
amine of the Hcy-derived thiazinane takes place due to its higher basicity compared to
the amine of the Cys-derived thiazolidne. The protonation results in inhibition of PET
quenching and selective signaling for Hcy. The presence of three electron-withdrawing
aldehyde groups makes the fluorophore highly reactive and enhances the Hcy detection
limit. Mulliken charge calculations reveal that the Hcy-derived thiazinane renders the
fluorophore phenoxide oxygen more electron-rich leading to fluorescence enhancement
as compared to the Cys-derived thiazolidine.
5.4 Experimental section
5.4.1 Materials
All chemicals were purchased from Sigma Aldrich and used as received. Ultra-pure water
(18.2 MΩ·cm at 25 °C) obtained from a Milli-Q direct water purification system was
utilized to prepare all aqueous solutions. All spectroscopic measurements were conducted
in DMSO:buffer (1:99) solutions.
5.4.2 Methods
1

H NMR and

13

C-NMR were recorded on a ARX-400 Advance Bruker spectrometer

performing at 400.13 MHz (1H) and 100.61 MHz (13C). All chemical shifts chemical
shifts (δ) were reported in ppm using DSS (sodium 2, 2-dimetyl-2-silapentane-5sulfonate) as an internal standard (=0.000) for 1H NMR studies. CF3COOD was used as
a NMR solvent to record 1H NMR spectra. 13C NMR of 5.1 was obtained in CDCl3 and
CF3COOD (1:8) solvent system . ESI-HRMS (high resolution mass spectrometry) spectra
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was recorded at the PSU Bioanalytical Mass Spectrometry Facility on a ThermoElectron
LTQ-Orbitrap high resolution mass spectrometer. IR spectrum was obtained by Fourier
transform infrared (FT-IR) spectroscopy operated on a Thermo Scientific Nicolet iS10
spectrophotometer equipped with a single-bounce diamond ATR attachment.
5.4.3 Spectrophotometric measurement
UV-visible spectra were recorded on a Cary 50 UV-Vis spectrophotometer (Agilent
Technologies). Fluorescence spectra were recorded on a Cary Eclipse fluorescence
spectrophotometer (Agilent Technologies) with slit widths set at 5 nm for both excitation
and emission, respectively. Fluorescence spectra were corrected for the wavelength
dependent response of the R928 photomultiplier tube with the help of a manufacturer
generated correction file. All spectrophotometric measurements were conducted at room
temperature.
5.4.3 Deproteinization of plasma
Deproteinization of plasma was carried out by following the procedure described in the
section 3.6.4.
5.4.4 Mulliken charges calculation
Molecular models of compounds 5.1, 5.1a and 5.1b were built and subjected to geometry
optimization and Mulliken population analysis using the PM7 hamiltonian in
MOPAC2012 [150, 151].
5.4.5 Synthesis of 5.1
Fluorescein (1 eqv, 7.52 mmol) was dissolved in a minimum amount of trifluoroacetic
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acid. Hexamethylene tetraamine (10 eqv, 75.23 mmol) was added slowly to the
fluorescein solution under Ar atmosphere at RT. Reaction mixture was stirred at 700C for
72 hrs under Ar and then at 100°C for extra 4 hrs. Afterward, 30 mL of 1N HCl was
added to the reaction mixture and stirred at 100 °C for additional 1hr. This resulted in the
formation of orange precipitates. The reaction mixture was left at RT for 15 hrs. Orange
precipitates were filtered, washed with water and dried under vacuum. Later, probe 5.1
was separated by column chromatography (CHCl3: MeOH, 98:2 and DCM: EtOAc 97:3).
Product was obtained as colorless solid with 2 % yield (62 mg). Rf = 0.3 (3% Ethyl
acetate in dichloromethane, SiO2); M.P. > 200 °C; 1H NMR (400 MHz, CDCl3) δ 10.74
(s, 1H, CHO), 10.62 (s, 1H, CHO), 9.93 (s, 1H, CHO), 8.17 (m, 1H), 7.84 (s, 1H), 7.74
(m, 2H), 7.25 (m, 2H), 6.94 (m, 1H);

13

C NMR (101 MHz, CDCl3) δ 189.7 (CHO),

187.6(overlapping, CHO), 166.3 (COOH), 153.7, 152.8 , 137.9 , 133.6 , 131.9, 127.8,
125.1, 122.4, 122, 120.8 , 117.9 , 115.5, 111.9, 110.8, 109.6 -108 (overlapping), 104.4;
max (film)/cm1 1738 (C=O);. Electrospray ionization (ESI) mass spectrometry (negative
electron ionization) m/z: 415.04610 (100% (M-H]+, calculated for C23H12O8 m/z:
416.05322 (100.0%).
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APPENDIX A : CHARACTERIZATION OF COMPOUNDS 4.1 AND 4.2

Figure A-1.1HNMR of 4.1 and 4.2
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Figure A-2 13CNMR of 4.1 and 4.2
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Figure A-3. Mass spectrum of 4.1 and 4.2
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APPENDIX B : CHARACTERIZATION OF COMPOUND 4.3 AND 4.4

Figure B-1. 1HNMR of 4.3 and 4.4
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Figure B-2. 13CNMR of 4.3 and 4.4
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Figure B-3. Mass spectrum of 4.3.and 4.4
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APPENDIX C : CHARACTERIZATION OF COMPOUND 4.5 AND 4.6

Figure C-1. 1HNMR of 4.5 and 4.5
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Figure C-2. 13CNMR of 4.5 and 4.6
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Figure C-3. Mass spectrum of 4.5 and 4.6
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APPENDIX D : CHARACTERIZATION OF COMPOUNDS 5.1

Figure D-1. 1HNMR of 5.1

Figure D-2. 13NMR of 5.1
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Figure D-3. Mass spectrum of 5.1
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APPENDIX E : COLORIMETRIC RESPONSE OF THIOLS TOWARDS 5.1

Figure E-1. Optical sensing behavior of 5.1 towards Hcy at pH 6.0, Time course absorbance spectral
changes of 5.1 with Hcy, Solutions are composed of 4 µM of 5.1 with 50 M of analyte in phosphate buffer
(100 mM, pH 6.0):DMSO 99:1 at 20 ºC

Figure E-2. Optical sensing behavior of 5.1 towards Cys at pH 6.0, Time course absorbance spectral
changes of 5.1 with Cys, Solutions are composed of 4 µM of 5.1 with 50 M of analyte in phosphate buffer
(100 mM, pH 6.0):DMSO 99:1 at 20 ºC
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APPENDIX F : ENERY MINIMIZED SIMULATED 3D STRUCTURE OF 5.1,
5.1A AND 5.1B'

Figure F-1. Energy minimized 3D structure of 5.1

Figure F-2. Energy minimized 3D structure of 5.1b (Hcy-5.1)
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Figure F-3. Energy minimized 3D structure of 5.1a (Cys-5.1).
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